Kevin is a Managing Director in CFGI’s Valuation Advisory practice bringing over 12 years of experience and specializing in the principles and methodologies leveraged for the valuation of businesses, intangible assets, and a variety of complex assets and liabilities. Key areas of expertise include customer relationships, developed technology, IPR&D, trademarks, non-competition agreements, deferred revenue, and contingent consideration & earnout liabilities since joining the firm in September of 2013 as a Consultant.
Kevin has worked primarily with pharmaceutical & biotechnology, technology & software, cannabis, and industrial & manufacturing clients. Kevin has executed a variety of projects including ASC 805 & IFRS 3 business combination transactions, ASC 350 & IAS 36 impairment testing, ASC 820 fair value measurements, contingent consideration valuations, and other ad hoc complex valuations.
Prior to CFGI, Kevin began his career as a Valuation Analyst at Duff & Phelps, where his industry focus included industrial products, aerospace & defense, healthcare, technology, and consumer products. Kevin’s focus included DCF analyses, equity and stock option valuations, business enterprise valuations, purchase price allocations, WACC calculations, intellectual property valuations, and goodwill impairment valuations.
Kevin graduated from Boston College’s Carroll School of Management with a Bachelor of Science in Finance and Management and Leadership.